Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iodofalan + lomustine
- Development stage
- Unknown
- Lead developer
- Telix Pharmaceuticals
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous (iodofalan), Oral (lomustine)
01
Overview
**Iodofalan + lomustine** is a combination regimen consisting of iodofalan (TLX101), an investigational radiopharmaceutical agent, and lomustine, a nitrosourea-class alkylating agent used in chemotherapeutic protocols. The combination is being explored primarily for recurrent glioblastoma, with iodofalan delivering targeted radiation to tumor cells and lomustine causing DNA alkylation and cross-linking, resulting in cytotoxicity. TLX101 is a small molecule that targets the LAT-1 (L-type amino acid transporter 1) highly expressed in malignant glioma cells, thereby delivering radioactive iodine directly into tumor tissue. This combination aims to achieve synergistic anti-tumor effects by leveraging both targeted radiotherapy (via TLX101) and systemic chemotherapeutic cytotoxicity (via lomustine).
- Brand names
- TLX101-TxTLX-101-TxTLX 101-Tx
- Other names
- iodofalan + lomustineTLX101 + lomustine
02
Targets
DNASLC7A5 (Large neutral amino acid transporter small subunit 1)
Beyond the preview
Go deeper on iodofalan + lomustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iodofalan + lomustine.